Patient finding is a partnership, not a transaction

In the rush to talk about algorithms and data, it’s easy to forget that finding rare disease patients is, at bottom, a relationship business. The technology only matters if the people who hold the data, the clinicians who act on it, and the partners who fund the work are all pulling in the same direction.

After a lot of these conversations, I’ve come to believe the difference between a project that lasts and one that fizzles is almost never the model. It’s whether the partnership was built right.

Aligned incentives, honestly stated

Everyone at the table wants something specific. Health systems want better care for their patients without new risk or burden. Clinicians want fewer missed patients, not more noise. Life-science partners want to reach the right populations and accelerate programs. Those goals are compatible, but only if you say them out loud and design for all of them, rather than optimizing for one and hoping the others come along.

A clear data boundary builds trust

The fastest way to lose a health-system partner is to be vague about data. Our stance is simple: patient data stays inside the system’s governed environment. Analysis runs where the data lives. Protected health information doesn’t get copied out to make the work happen. Far from constraining the partnership, that boundary is what the partnership is built on. Trust is what lets it scale past the first pilot.

Sustainable beats flashy

A one-time analysis that impresses in a demo and then gathers dust helps no one. The partnerships worth building are the ones that keep working: definitions that stay current, results clinicians keep coming back to, value that compounds over time. We’d rather build something a partner relies on for years than something they applaud once.

What we bring, and what we don’t

We bring the platform, the governed and KOL-validated definitions, and decades of diagnostic experience. What we don’t bring is a desire to own our partners’ data or their patient relationships. Those stay where they belong. Our job is to help the right patients become visible to the people equipped to help them.

That’s the kind of partnership that actually moves rare disease care forward. If that’s how your organization likes to work, let’s talk.

— Travis Musick, Co-founder & CRO, Sagacity Diagnostics

This article reflects the author’s perspective and is not medical or investment advice.